CA3187835A1 - Substituted piperidine compounds and their use - Google Patents
Substituted piperidine compounds and their useInfo
- Publication number
- CA3187835A1 CA3187835A1 CA3187835A CA3187835A CA3187835A1 CA 3187835 A1 CA3187835 A1 CA 3187835A1 CA 3187835 A CA3187835 A CA 3187835A CA 3187835 A CA3187835 A CA 3187835A CA 3187835 A1 CA3187835 A1 CA 3187835A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- azabicyclo
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020122864 | 2020-07-17 | ||
| JP2020-122864 | 2020-07-17 | ||
| PCT/JP2021/026649 WO2022014680A1 (ja) | 2020-07-17 | 2021-07-15 | 置換ピペリジン化合物及びその用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3187835A1 true CA3187835A1 (en) | 2022-01-20 |
Family
ID=79291962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3187835A Pending CA3187835A1 (en) | 2020-07-17 | 2021-07-15 | Substituted piperidine compounds and their use |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11479552B2 (https=) |
| EP (1) | EP4151277B1 (https=) |
| JP (1) | JP7190612B2 (https=) |
| KR (1) | KR20230040953A (https=) |
| CN (3) | CN119235864A (https=) |
| AR (1) | AR122973A1 (https=) |
| AU (1) | AU2021308053A1 (https=) |
| BR (1) | BR112022026161A2 (https=) |
| CA (1) | CA3187835A1 (https=) |
| CL (1) | CL2022003666A1 (https=) |
| CO (1) | CO2022018446A2 (https=) |
| DK (1) | DK4151277T3 (https=) |
| FI (1) | FI4151277T3 (https=) |
| IL (1) | IL299125B2 (https=) |
| JO (1) | JOP20220345A1 (https=) |
| LT (1) | LT4151277T (https=) |
| MX (1) | MX2022016388A (https=) |
| PE (1) | PE20231103A1 (https=) |
| PH (1) | PH12022553488A1 (https=) |
| TW (1) | TWI888599B (https=) |
| UA (1) | UA129636C2 (https=) |
| WO (1) | WO2022014680A1 (https=) |
| ZA (1) | ZA202213562B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4065585B1 (en) | 2019-11-25 | 2025-08-20 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP7591592B2 (ja) * | 2022-01-14 | 2024-11-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 置換ピペリジン化合物を含有する医薬 |
| JPWO2023136279A1 (https=) * | 2022-01-14 | 2023-07-20 | ||
| WO2024075825A1 (ja) * | 2022-10-07 | 2024-04-11 | キッセイ薬品工業株式会社 | シクロペンタン化合物 |
| EP4611745A1 (en) * | 2022-10-31 | 2025-09-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2024128305A1 (ja) | 2022-12-16 | 2024-06-20 | 第一三共株式会社 | ２－アザビシクロ［３．１．１］ヘプタン化合物 |
| EP4719397A1 (en) | 2023-06-02 | 2026-04-08 | Takeda Pharmaceutical Company Limited | Use of an orexin 2 receptor agonist for improving respiratory function during sleep |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2025137359A1 (en) | 2023-12-20 | 2025-06-26 | Eisai R&D Management Co., Ltd. | Assay methods to identify a disease |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG34208A1 (en) | 1995-03-01 | 1996-12-06 | Guy Andrew Vaz | Blast and fragment resistant polyurethane boot sole for safety footwear |
| EP0828751A4 (en) | 1995-05-05 | 1999-01-20 | Human Genome Sciences Inc | HUMAN NEUROPEPTIDE RECEPTOR |
| US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
| US6159605A (en) | 1997-02-18 | 2000-12-12 | Dainichiseika Color & Chemicals Mfg. Co., Ltd. | Ink-jet recording sheet |
| US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| KR100327888B1 (ko) | 1999-07-14 | 2002-03-09 | 정숭렬 | 도로포장 파손촉진 시험장치의 무선제어 시스템 |
| AU2004274309B2 (en) * | 2003-09-22 | 2010-04-08 | Msd K.K. | Novel piperidine derivative |
| EP1805183B1 (en) | 2004-10-20 | 2010-12-29 | NeuroSearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
-
2021
- 2021-07-15 TW TW110126031A patent/TWI888599B/zh active
- 2021-07-15 DK DK21842047.9T patent/DK4151277T3/da active
- 2021-07-15 PE PE2022003006A patent/PE20231103A1/es unknown
- 2021-07-15 PH PH1/2022/553488A patent/PH12022553488A1/en unknown
- 2021-07-15 CN CN202411459551.4A patent/CN119235864A/zh active Pending
- 2021-07-15 AR ARP210101982A patent/AR122973A1/es unknown
- 2021-07-15 UA UAA202204882A patent/UA129636C2/uk unknown
- 2021-07-15 EP EP21842047.9A patent/EP4151277B1/en active Active
- 2021-07-15 WO PCT/JP2021/026649 patent/WO2022014680A1/ja not_active Ceased
- 2021-07-15 IL IL299125A patent/IL299125B2/en unknown
- 2021-07-15 AU AU2021308053A patent/AU2021308053A1/en active Pending
- 2021-07-15 CN CN202180044081.3A patent/CN115884971B/zh active Active
- 2021-07-15 US US17/376,452 patent/US11479552B2/en active Active
- 2021-07-15 CN CN202411462171.6A patent/CN119258067A/zh active Pending
- 2021-07-15 CA CA3187835A patent/CA3187835A1/en active Pending
- 2021-07-15 FI FIEP21842047.9T patent/FI4151277T3/fi active
- 2021-07-15 LT LTEPPCT/JP2021/026649T patent/LT4151277T/lt unknown
- 2021-07-15 KR KR1020227044679A patent/KR20230040953A/ko active Pending
- 2021-07-15 JP JP2022536446A patent/JP7190612B2/ja active Active
- 2021-07-15 BR BR112022026161A patent/BR112022026161A2/pt unknown
- 2021-07-15 MX MX2022016388A patent/MX2022016388A/es unknown
-
2022
- 2022-12-14 ZA ZA2022/13562A patent/ZA202213562B/en unknown
- 2022-12-20 CL CL2022003666A patent/CL2022003666A1/es unknown
- 2022-12-20 CO CONC2022/0018446A patent/CO2022018446A2/es unknown
- 2022-12-21 JO JOJO/P/2022/0345A patent/JOP20220345A1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11479552B2 (en) | Substituted piperidine compounds and their use | |
| BR122021004509B1 (pt) | Sais de inibidor de pi3k e processos para seu preparo | |
| WO2022166741A1 (zh) | 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途 | |
| WO2017036318A1 (zh) | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 | |
| US20260098011A1 (en) | Deuterated organic compounds and uses thereof | |
| EP3022201A1 (en) | Autotaxin inhibitors | |
| KR101800140B1 (ko) | 벤조티아졸론 화합물 | |
| EA020010B1 (ru) | БИЦИКЛИЧЕСКИЕ ТИАЗОЛЫ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 РЕЦЕПТОРОВ | |
| WO2020011257A1 (zh) | 一种稠合三环γ-氨基酸衍生物的组合物及其制备 | |
| TW202340145A (zh) | 氘化有機化合物及其用途 | |
| TW202333671A (zh) | 氘化有機化合物及其用途 | |
| EP4438602A1 (en) | Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof | |
| RU2840772C1 (ru) | Замещенные пиперидиновые соединения и их применение | |
| JP7591592B2 (ja) | 置換ピペリジン化合物を含有する医薬 | |
| EA045865B1 (ru) | Замещенные пиперидиновые соединения и их применение | |
| TWI922338B (zh) | 取代哌啶化合物及其用途 | |
| HK40083601A (en) | Substituted piperidine compound and application thereof | |
| BR112017018312B1 (pt) | Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k | |
| JP2007031311A (ja) | キヌクリジン誘導体含有医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241118 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250626 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250626 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250707 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250808 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250902 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250902 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250903 |